Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.
Panelists discuss how the PERSEUS trial demonstrated superior progression-free survival with daratumumab-VRd compared to VRd alone in patients with transplant-eligible newly diagnosed multiple myeloma ...
The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback